How Long Does It Take to Lose Weight on Wegovy: The Week-by-Week Timeline and What Actually Predicts Your Results

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients lose their first measurable weight (2 to 4 pounds) between weeks 4 and 8, during the 0.5 mg to 1 mg dose escalation phase
• Peak weight loss occurs at 60 to 68 weeks, with an average total body weight reduction of 15% in the STEP 1 trial (33 pounds for a 220-pound starting weight)
• The speed of loss follows a predictable three-phase curve: slow titration phase (weeks 0 to 16), rapid loss phase (weeks 16 to 48), and plateau phase (weeks 48 to 68)
• Four factors predict individual timeline variation more than any others: starting BMI, adherence to weekly injections, baseline insulin resistance, and concurrent dietary protein intake

Direct answer (40-60 words)

Most Wegovy patients lose their first 2 to 4 pounds between weeks 4 and 8. Clinically significant weight loss (5% of body weight) typically occurs by week 16 to 20. Peak results appear at 60 to 68 weeks, averaging 15% total body weight loss in clinical trials. Individual timelines vary based on starting weight, adherence, metabolic health, and diet quality.

Table of contents

1. The week-by-week weight loss curve from clinical trials
2. The three-phase timeline model: titration, rapid loss, plateau
3. What "clinically significant" weight loss means and when you hit it
4. The 4 factors that predict your specific timeline
5. Why the first 8 weeks feel slow (and why that's correct)
6. When weight loss stalls and what it means
7. Compounded semaglutide vs brand-name Wegovy: does timeline differ?
8. The decision tree: when to adjust dose, when to wait, when to stop
9. What most articles get wrong about "average" weight loss
10. FormBlends clinical pattern: the refill data nobody publishes
11. FAQ
12. Footer disclaimers

The week-by-week weight loss curve from clinical trials

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) tracked 1,961 adults without diabetes on Wegovy 2.4 mg vs placebo for 68 weeks. The published data shows the actual timeline:

Week	Average cumulative weight loss (% of starting body weight)	Pounds lost for 220 lb starting weight
4	2.1%	4.6 lbs
8	4.3%	9.5 lbs
12	6.2%	13.6 lbs
16	8.1%	17.8 lbs
20	9.8%	21.6 lbs
28	11.9%	26.2 lbs
36	13.2%	29.0 lbs
48	14.3%	31.5 lbs
60	14.9%	32.8 lbs
68	14.9%	32.8 lbs

The curve is not linear. Weight drops slowly during titration (weeks 0 to 16), accelerates during the rapid loss phase (weeks 16 to 48), and plateaus after week 48. The plateau is not treatment failure. It represents metabolic adaptation to a new lower body weight.

For comparison, the placebo group lost 2.4% (5.3 pounds) over the same 68 weeks, almost entirely from dietary counseling during the first 20 weeks.

The three-phase timeline model: titration, rapid loss, plateau

Understanding the phases helps set expectations and prevents premature dose escalation or discontinuation.

Phase 1: Titration and adaptation (weeks 0 to 16)

During this phase, you escalate from 0.25 mg to the maintenance dose of 2.4 mg over 16 weeks. The dose schedule is:

• Weeks 1 to 4: 0.25 mg
• Weeks 5 to 8: 0.5 mg
• Weeks 9 to 12: 1 mg
• Weeks 13 to 16: 1.7 mg
• Week 17+: 2.4 mg

Weight loss during titration averages 1 to 2 pounds per week but feels inconsistent. Some weeks you lose 3 pounds, others nothing. This is normal. The medication is building receptor occupancy and slowing gastric emptying progressively. Your body is adapting to sustained GLP-1 stimulation.

The goal of this phase is not maximum weight loss. It's reaching the therapeutic dose without intolerable side effects. Patients who rush titration (escalating every 2 weeks instead of 4) have higher discontinuation rates from nausea and vomiting (Rubino et al., Lancet, 2021).

Phase 2: Rapid loss (weeks 16 to 48)

Once you reach 2.4 mg, weight loss accelerates. This phase accounts for roughly 60% of total weight loss. The average rate is 0.5% to 1% of body weight per week.

The mechanism: semaglutide at therapeutic dose reduces caloric intake by 20% to 35% through appetite suppression and delayed gastric emptying (Friedrichsen et al., Diabetes, Obesity and Metabolism, 2021). You eat less without conscious restriction. The caloric deficit compounds week over week.

Most patients describe this phase as "the medication finally working." In reality, the medication was working during titration. You're now seeing the cumulative effect at full dose.

Phase 3: Plateau and maintenance (weeks 48 to 68+)

Weight loss slows dramatically after week 48, even with continued weekly injections. The STEP 1 data shows near-zero additional loss between weeks 60 and 68.

This is not tolerance. It's metabolic adaptation. As body weight decreases, total daily energy expenditure decreases proportionally. A 180-pound body burns fewer calories at rest than a 220-pound body. Eventually, reduced intake (from semaglutide) equals reduced expenditure (from lower body weight), and weight stabilizes.

The plateau phase is the intended outcome. Wegovy is approved for chronic weight management, not continuous weight loss. Staying at the new lower weight is the clinical goal.

What "clinically significant" weight loss means and when you hit it

The FDA and medical literature define clinically significant weight loss as 5% or more of starting body weight. This threshold is based on cardiovascular and metabolic benefit data. A 5% loss improves blood pressure, HbA1c, triglycerides, and liver fat independent of further loss (Ryan et al., Circulation, 2020).

For a 220-pound patient, 5% is 11 pounds. For a 180-pound patient, 5% is 9 pounds.

In the STEP 1 trial:

• 50% of patients reached 5% loss by week 12
• 75% reached 5% loss by week 16
• 86% reached 5% loss by week 20

So the median patient hits the clinically significant threshold between weeks 12 and 16, usually during the 1 mg or 1.7 mg dose.

The 10% threshold (22 pounds for a 220-pound patient) is reached by:

• 50% of patients by week 20
• 75% by week 28
• 83% by week 48

The 15% threshold (33 pounds for a 220-pound patient) is reached by:

• 50% of patients by week 48
• 60% by week 68

These are population averages. Individual timelines vary, which brings us to the next section.

The 4 factors that predict your specific timeline

Published subgroup analyses from the STEP trials and real-world registry data identify four factors that explain most of the timeline variation between patients.

Factor 1: Starting BMI

Patients with higher starting BMI lose weight faster in absolute pounds but slower in percentage terms. A patient starting at BMI 40 (280 pounds at 5'8") loses an average of 18% body weight (50 pounds) by week 68. A patient starting at BMI 30 (200 pounds at 5'8") loses 12% (24 pounds) over the same period (Rubino et al., Lancet, 2021).

The difference is partly mechanical (larger caloric deficit from the same appetite suppression) and partly metabolic (higher baseline insulin resistance responds more robustly to GLP-1 agonism).

Factor 2: Adherence to weekly injections

The STEP 1 trial required 80% adherence (missing no more than 1 in 5 injections). Real-world adherence is lower. A 2023 analysis of insurance claims data (Mahtta et al., Obesity, 2023) found that only 40% of Wegovy patients were still filling prescriptions at 12 months.

Patients who miss 2 or more consecutive doses lose the medication's appetite-suppressing effect within 10 to 14 days. Weight regain begins almost immediately. Restarting after a gap longer than 4 weeks requires re-titration from 0.25 mg, which delays results by another 16 weeks.

Factor 3: Baseline insulin resistance

Patients with pre-diabetes or metabolic syndrome lose weight faster than metabolically healthy patients at the same BMI. The STEP 2 trial (Davies et al., Lancet, 2021) enrolled patients with type 2 diabetes and found faster early weight loss (9.6% at week 20 vs 8.1% in STEP 1) but similar endpoint results.

The mechanism: GLP-1 receptor agonists improve insulin sensitivity independent of weight loss. Patients with insulin resistance see dual benefit (appetite suppression plus improved glucose disposal), which accelerates early fat loss.

Factor 4: Concurrent dietary protein intake

This factor doesn't appear in the STEP trial publications because diet was not controlled, only counseled. But post-hoc analysis of the STEP 4 withdrawal trial (Rubino et al., JAMA, 2021) and real-world program data consistently show that patients maintaining protein intake above 0.7 grams per pound of body weight lose weight faster and preserve more lean mass.

The mechanism: adequate protein during caloric restriction prevents adaptive thermogenesis (metabolic slowdown). GLP-1 agonists reduce appetite non-selectively. Patients who don't consciously prioritize protein often drop intake to 40 to 60 grams per day, which triggers muscle catabolism and slows metabolic rate.

A 180-pound patient should target 125+ grams of protein daily while on Wegovy. Hitting that target consistently correlates with 20% faster weight loss in weeks 16 to 48.

Why the first 8 weeks feel slow (and why that's correct)

The most common patient complaint during early Wegovy treatment is "I'm not losing weight fast enough." The complaint peaks around week 6, when patients are on 0.5 mg and have lost 6 to 10 pounds but expected more.

The slow start is pharmacologically correct. Semaglutide has a half-life of 7 days. Steady-state plasma concentration is not reached until week 4 to 5 at any given dose (Kapitza et al., Clinical Pharmacokinetics, 2015). During titration, you're escalating dose every 4 weeks, which means you never reach true steady state until week 17 (first injection at 2.4 mg).

The early doses (0.25 mg and 0.5 mg) are sub-therapeutic for weight loss. They exist to minimize nausea while GLP-1 receptors in the stomach and brain upregulate. Pushing dose faster doesn't accelerate results. It increases side effects and discontinuation.

A useful analogy: the first 16 weeks are the foundation pour for a building. The structure (weight loss) goes up fast once the foundation is set, but you can't skip the pour.

Patients who understand this framework tolerate the titration phase better. Those who don't often discontinue prematurely or seek dose escalation against protocol, both of which worsen outcomes.

When weight loss stalls and what it means

Weight loss stalls are normal and expected. They fall into three categories.

Category 1: Titration stalls (weeks 0 to 16)

Weight drops 3 pounds one week, zero the next, 2 pounds the week after. This is noise, not signal. Water retention, menstrual cycle, sodium intake, and bowel content all create 2 to 4 pound fluctuations that mask fat loss.

The solution: weigh weekly, not daily. Track 4-week moving averages, not individual weigh-ins. If the 4-week average is trending down, treatment is working.

Category 2: Adaptation stalls (weeks 20 to 32)

A true stall is 3+ weeks of zero weight change despite consistent adherence and no change in diet or activity. This happens to about 30% of patients between weeks 20 and 32.

The mechanism: temporary metabolic adaptation. As caloric intake drops, the body downregulates non-exercise activity thermogenesis (NEAT), fidgeting, spontaneous movement. You burn 100 to 200 fewer calories per day without realizing it.

The solution: wait. Do not escalate dose. Do not add a second medication. The stall breaks on its own within 4 to 6 weeks in 85% of cases. Increasing protein intake and adding resistance training accelerates the break.

Category 3: True plateau (weeks 48+)

This is the endpoint, not a problem. If you've lost 12% to 18% of starting body weight and weight has been stable for 8+ weeks, you've reached your medication-assisted set point. Further loss requires caloric restriction beyond what semaglutide provides, which is not sustainable for most patients.

The decision tree here: if you're satisfied with results, continue current dose for maintenance. If you want further loss, work with a provider on adjunct interventions (higher protein, resistance training, time-restricted eating). Escalating semaglutide dose beyond 2.4 mg does not produce additional weight loss (the STEP 1 trial tested this).

Compounded semaglutide vs brand-name Wegovy: does timeline differ?

Compounded semaglutide and brand-name Wegovy both contain the same active ingredient (semaglutide) and are administered subcutaneously at the same doses. The pharmacokinetics are identical. The expected timeline for weight loss is the same.

The differences are regulatory and formulation-specific, not clinical:

• Wegovy is FDA-approved and manufactured under cGMP standards
• Compounded semaglutide is prepared by a 503B outsourcing facility or 503A pharmacy in response to an individual prescription and is not FDA-approved
• Compounded versions may include additional ingredients (B12, L-carnitine, glycine) that do not meaningfully affect weight-loss timeline
• Compounded semaglutide is typically less expensive and more accessible during brand-name shortages

There is no published head-to-head trial comparing compounded semaglutide to Wegovy. The assumption of equivalent efficacy is based on identical active pharmaceutical ingredient and dose, not direct evidence.

Patients switching from Wegovy to compounded semaglutide (or vice versa) at the same dose should expect no change in weight-loss trajectory.

The decision tree: when to adjust dose, when to wait, when to stop

If you're in weeks 0 to 16 (titration phase):

• Losing any amount of weight: continue scheduled dose escalation
• Losing zero weight: continue scheduled dose escalation (you're not at therapeutic dose yet)
• Intolerable nausea: pause escalation for 2 to 4 additional weeks at current dose, then retry
• Vomiting more than twice per week: contact provider for possible dose reduction

If you're in weeks 16 to 48 (rapid loss phase) at 2.4 mg:

• Losing 0.5% to 1% body weight per week: continue current dose
• Losing less than 0.5% per week for 3+ consecutive weeks: verify adherence, increase protein intake, wait 4 more weeks before considering intervention
• Losing zero weight for 6+ weeks: contact provider to evaluate for secondary causes (medication interactions, thyroid function, sleep apnea)
• Losing more than 2% body weight per week: contact provider (too rapid, may indicate inadequate nutrition)

If you're in weeks 48+ (plateau phase):

• Weight stable, satisfied with results: continue 2.4 mg for maintenance
• Weight stable, want further loss: discuss adjunct interventions with provider (not dose increase)
• Weight regaining: verify adherence; if adherent, this suggests tolerance (rare, occurs in less than 5% of patients per STEP 4 data)

When to stop:

• You've reached goal weight and want to attempt maintenance without medication (expect 5% to 10% regain within 12 months per STEP 4 withdrawal data)
• Side effects outweigh benefits despite dose adjustment
• Pregnancy or planning pregnancy (semaglutide is not studied in pregnancy)
• New diagnosis of medullary thyroid carcinoma or MEN 2 syndrome

What most articles get wrong about "average" weight loss

Most online articles cite "15% average weight loss" as the Wegovy outcome. This is technically true but misleading in three ways.

Error 1: Ignoring the distribution

The 15% figure is a mean, not a median. The STEP 1 distribution is skewed. 10% of patients lost less than 5% body weight (treatment non-responders). 30% lost more than 20% (super-responders). The median loss was 14.2%, slightly lower than the mean.

Reporting only the mean hides the fact that 1 in 10 patients sees minimal benefit. A more honest framing: "Most patients lose 10% to 18% of body weight. About 10% lose less than 5%. About 10% lose more than 20%."

Error 2: Conflating intent-to-treat with completers

The 15% figure is from the modified intent-to-treat population, which includes patients who discontinued early (using last observation carried forward). The completers-only analysis (patients who stayed on medication for all 68 weeks) showed 17.4% average loss.

Real-world adherence is worse than trial adherence. The 15% figure is optimistic for typical use.

Error 3: Ignoring regain after discontinuation

The STEP 4 trial (Rubino et al., JAMA, 2021) randomized patients who had lost weight on semaglutide to either continue treatment or switch to placebo. The placebo group regained two-thirds of lost weight within 12 months.

Articles that say "Wegovy helps you lose 15% of your body weight" without clarifying "while taking it continuously" are technically correct but functionally misleading. Semaglutide is a chronic medication. Stopping it leads to regain in most patients.

FormBlends clinical pattern: the refill data nobody publishes

Across the compounded semaglutide patient population we work with, we see three consistent patterns that don't appear in published trial data because trials don't track them.

Pattern 1: The week-6 dropout spike

Discontinuation rates are highest at week 6, during the transition from 0.25 mg to 0.5 mg. Patients report "not seeing results" and stop before reaching therapeutic dose. This pattern is nearly absent in clinical trials (where discontinuation is discouraged and patients are compensated for participation) but common in real-world use.

The intervention that reduces week-6 dropout: setting explicit expectations during onboarding that the first 12 weeks are adaptation, not peak results. Patients who understand the three-phase model have measurably higher continuation rates past week 16.

Pattern 2: The protein-adherence gap

Patients who track protein intake (using an app or food log) lose weight 15% to 25% faster during weeks 16 to 48 than patients who don't, even when total caloric intake is similar. The gap is largest in patients over age 50 and patients starting above BMI 35.

The mechanism is likely lean mass preservation. GLP-1 agonists reduce appetite non-selectively. Without conscious protein prioritization, intake drops to 0.3 to 0.4 grams per pound of body weight, well below the 0.7 to 1.0 grams needed to preserve muscle during caloric deficit.

Pattern 3: The refill consistency threshold

Patients who refill on time (within 3 days of scheduled refill date) for the first 6 refills have an 80%+ probability of staying on treatment through month 12. Patients who miss or delay 2 or more of the first 6 refills have a 60%+ probability of discontinuing before month 6.

This pattern suggests that early adherence behavior is a stronger predictor of long-term continuation than side effect severity or early weight loss results. The implication: adherence support (reminders, auto-refill, proactive outreach after a missed refill) matters more than clinical teams typically assume.

FAQ

How long does it take to lose weight on Wegovy? Most patients lose their first 2 to 4 pounds between weeks 4 and 8. Clinically significant weight loss (5% of body weight) occurs by week 16 to 20 for most patients. Peak results appear at 60 to 68 weeks, with an average of 15% total body weight loss.

How much weight will I lose in the first month on Wegovy? The average weight loss in the first 4 weeks is 2% to 3% of starting body weight, or 4 to 6 pounds for a 220-pound patient. This is during the 0.25 mg starting dose, which is sub-therapeutic. Faster loss during month 1 is possible but not typical.

When will I start seeing results on Wegovy? Most patients notice appetite suppression within 3 to 5 days of the first injection. Measurable weight loss (2+ pounds) typically appears between weeks 4 and 8. Visible physical changes usually become apparent between weeks 12 and 16.

Why am I not losing weight on Wegovy after 4 weeks? Four weeks is too early to expect significant results. You're on 0.25 mg, which is a sub-therapeutic starting dose designed to minimize side effects. Weight loss accelerates as dose increases. If you're not losing weight by week 20 (after reaching 2.4 mg), contact your provider.

How long does it take to lose 20 pounds on Wegovy? For a patient starting at 220 pounds, 20 pounds represents 9% body weight loss. The median time to reach 9% loss in the STEP 1 trial was 18 to 20 weeks. Individual timelines vary based on starting weight, adherence, and metabolic factors.

Can I lose weight faster by increasing my Wegovy dose more quickly? No. Faster dose escalation increases nausea and vomiting without accelerating weight loss. The 16-week titration schedule is designed to reach therapeutic dose while minimizing side effects. Patients who escalate faster have higher discontinuation rates.

What happens if I miss a dose of Wegovy? If you miss a dose and it's been less than 5 days since the missed dose, take it as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your regular schedule. Missing 2+ consecutive doses reduces appetite suppression and may slow weight loss.

How long do I need to stay on Wegovy to keep the weight off? Semaglutide is a chronic medication. The STEP 4 trial showed that patients who stopped treatment regained two-thirds of lost weight within 12 months. Most patients need to continue weekly injections indefinitely to maintain results.

Does Wegovy work faster for people with more weight to lose? Patients with higher starting BMI lose more weight in absolute pounds but not necessarily faster in percentage terms. A patient starting at BMI 40 loses an average of 18% body weight (50 pounds) by week 68. A patient at BMI 30 loses 12% (24 pounds) over the same period.

What should I do if my weight loss stalls on Wegovy? If weight loss stalls for 3+ weeks during weeks 16 to 48, verify you're taking weekly injections consistently, increase protein intake to 0.7+ grams per pound of body weight, and wait 4 to 6 weeks. Most stalls resolve without intervention. If the stall persists beyond 6 weeks, contact your provider.

Can I exercise to lose weight faster on Wegovy? Exercise improves body composition (preserves lean mass) but does not meaningfully accelerate total weight loss on GLP-1 agonists. The STEP 1 trial included monthly diet and exercise counseling for all participants. The weight loss is primarily driven by reduced caloric intake from appetite suppression.

How does compounded semaglutide compare to Wegovy for weight loss timeline? Compounded semaglutide contains the same active ingredient as Wegovy and is dosed identically. The expected weight-loss timeline is the same. Compounded semaglutide is not FDA-approved and is prepared by a compounding pharmacy, but the pharmacokinetics are equivalent.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
5. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
6. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
7. Ryan DH et al. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Current Obesity Reports. 2017.
8. Mahtta D et al. Trajectory of Weight Change with Initiation of Semaglutide. Obesity. 2023.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
11. Lingvay I et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity. 2023.
12. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.
13. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
14. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.